Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1999
Business Overview: A worldwide developer, manufacturer, and marketer of medical devices for less invasive procedures. The company operates in four geographic segments: United States, Europe, Japan, and Emerging Markets. The reporting period includes the full impact of the Schneider Worldwide acquisition completed in the third quarter of 1998.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 1999 | Q1 1998 |
|---|---|---|
| Net Sales | $708 | $453 |
| Gross Profit | $478 | $315 |
| Gross Margin | 67.5% | 69.5% |
| Operating Income | $189 | $96 |
| Net Income | $100 | $60 |
| Diluted EPS | $0.25 | $0.15 |
| Cash Flow from Operations | $137 | $34 |
| Cash and Equivalents (Ending) | $110 | $143 |
| Total Debt (Short-term + Long-term) | $2,276 | $1,364 |
Note: Total debt for Q1 1999 includes $1,016 million in commercial paper (refinanced to revolving credit facilities) and $1,260 million in long-term debt. Q1 1998 debt figures are derived from the balance sheet provided for Dec 31, 1998 ($1,027M commercial paper + $1,364M long-term) as Q1 1998 balance sheet data is not explicitly detailed in the text, though cash flow indicates a net decrease in commercial paper.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 56% to $708 million. On a pro forma basis including Schneider, sales grew 30%. U.S. revenues rose 66% to $441 million, driven largely by coronary stent sales ($105 million).
- Profitability: Net income increased 67% to $100 million. Operating income more than doubled to $189 million.
- Margins: Gross margin decreased 200 basis points to 67.5% due to supply chain integration challenges, inventory write-downs, and high manufacturing costs. SG&A expenses as a percentage of sales improved from 35% to 29%.
- Debt Structure: Interest expense surged from $6 million to $35 million due to higher debt balances from the Schneider acquisition. The company refinanced $1.7 billion of commercial paper into revolving credit facilities at a weighted average rate of 5.5%.
- Amortization: Amortization expense increased 188% to $23 million, primarily due to intangibles from the Schneider purchase.
Outlook, Risks, and Management Commentary
Guidance and Outlook
- Supply Chain: Management is executing a global supply chain optimization program to lower inventory and manufacturing costs, expected to be completed by the end of 1999.
- Financing: The company intends to refinance a portion of its credit facilities with permanent financing (convertible or equity securities) in 1999 to comply with debt-to-net-worth covenants.
- Capital Needs: Projected cash needs for the remainder of 1999 include $100 million in capital expenditures, $40 million in tax payments, and $128 million in acquisition-related obligations.
Material Risks and Contingencies
- Legal Proceedings: The company is involved in extensive patent litigation with Advanced Cardiovascular Systems (ACS), Cordis (Johnson & Johnson), Arterial Vascular Engineering (AVE), and others. A judgment of $10.8 million was entered against the company by C.R. Bard, Inc., which is currently being appealed.
- Regulatory Investigations: The U.S. Department of Justice is investigating the voluntary recall of the NIR ON Ranger with Sox coronary stent system. The SEC is reviewing the company's purchase price allocation for the Schneider acquisition and prior revenue recognition practices.
- Supplier Dependency: The NIR coronary stent, representing ~20% of worldwide sales, is supplied by Medinol LTD. Supply interruptions or price fluctuations could materially impact results.
- Year 2000 Compliance: The company has expended over $100 million on Y2K compliance. While management believes systems are compliant, risks remain regarding third-party service providers.
Investor Verification Checklist
- Debt Covenants: Verify the company's ability to meet the 70% debt-to-net-worth ratio requirement through December 31, 1999, and the planned equity/debt refinancing.
- Legal Exposure: Monitor the status of the C.R. Bard appeal and the outcomes of pending patent trials with ACS, Cordis, and AVE, which could result in injunctions or significant damages.
- SEC Review: Track the outcome of the SEC's review of the Schneider purchase price allocation and revenue recognition, which could lead to restatements of prior results.
- Supply Chain Execution: Assess progress on the global supply chain initiative to determine if gross margins can recover to historical levels.
- Japan Receivables: Evaluate the collectability of receivables in Japan given the noted deterioration of the Japanese economy.